CheckMyClinic
Independent analysis of UK private clinic regulation and compliance
Enforcement WatchEnforcement analysisASAMedicine advertisingWeight managementEnforcement

ASA upholds Black Friday Mounjaro ad complaints

The ASA ruled against Juniper and Voy for Black Friday promotions of Mounjaro and Wegovy — finding both POM advertising breaches and social irresponsibility for creating false urgency around prescription medicines.

What happened

The ASA upheld two complaints against online weight-loss providers for Black Friday 2025 advertising. Juniper ran Instagram ads promoting Mounjaro with time-limited Black Friday discounts. Voy sent email promotions for Wegovy and tirzepatide with countdown urgency. Both breached CAP Code rules 12.12 (POM advertising ban) and 1.3 (social responsibility).

This is significant because the ASA applied both rules together — the POM ban and the social responsibility requirement — creating a double violation that makes the ruling harder to dismiss as a technicality.

Who this affects

What it means

The "double breach" pattern matters. Even if you avoid naming the POM directly, creating urgency around weight-loss treatment availability or pricing can still breach social responsibility rules. The ASA is looking at the overall pressure tactics, not just whether the drug name appears.

What to watch next

With the ASA's AI monitoring system now live, similar seasonal promotions will likely be caught automatically. Expect pre-Christmas and New Year enforcement sweeps targeting weight-loss ads.

Disclaimer: This article is for informational purposes only and does not constitute legal advice.